Emma Scott

8PUBLICATIONS
14CO-AUTHORS
Haematological tumoursInnate immunityMolecular targetsPredictive and prognostic markersMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 14, 2026
Tissue-specific factors that govern the sialoglycan-Siglec axis in cancer.

|May 26, 2025
A general and accessible approach to enrichment and characterisation of natural anti-Neu5Gc antibodies from human samples.

Esme Hutton, Yumiko Uno, Emma Scott

|Mar 06, 2024
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.

Rebecca Garnham, Daniel Geh, Ryan Nelson

|Aug 07, 2023
ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.

Emma Scott, Emily Archer Goode, Rebecca Garnham

|Jul 29, 2023
CDC20 Is Regulated by the Histone Methyltransferase, KMT5A, in Castration-Resistant Prostate Cancer.

Zainab A H Alebady, Mahsa Azizyan, Sirintra Nakjang

|Jul 28, 2022
Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer.

Emma Scott, Rebecca Garnham, Kathleen Cheung

Pageof 2

Frequent Collaborators

3 joint publications

Jennifer Munkley

2 joint publications

Craig Robson

2 joint publications

Kelly Coffey

1 joint publications

Mahsa Azizyan